1. Home
  2. AMCX vs PBYI Comparison

AMCX vs PBYI Comparison

Compare AMCX & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AMC Networks Inc.

AMCX

AMC Networks Inc.

HOLD

Current Price

$10.52

Market Cap

411.2M

ML Signal

HOLD

Logo Puma Biotechnology Inc

PBYI

Puma Biotechnology Inc

HOLD

Current Price

$8.30

Market Cap

428.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMCX
PBYI
Founded
1980
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Cable & Other Pay Television Services
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
411.2M
428.1M
IPO Year
2011
2011

Fundamental Metrics

Financial Performance
Metric
AMCX
PBYI
Price
$10.52
$8.30
Analyst Decision
Sell
Analyst Count
4
0
Target Price
$7.33
N/A
AVG Volume (30 Days)
439.1K
376.3K
Earning Date
05-08-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
132.55
N/A
EPS
N/A
N/A
Revenue
$2,311,801,000.00
$27,685,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.41
$3.03
52 Week High
$11.13
$8.66

Technical Indicators

Market Signals
Indicator
AMCX
PBYI
Relative Strength Index (RSI) 60.28 59.21
Support Level $9.31 $6.50
Resistance Level N/A $8.42
Average True Range (ATR) 0.48 0.39
MACD 0.04 0.01
Stochastic Oscillator 70.37 65.14

Price Performance

Historical Comparison
AMCX
PBYI

About AMCX AMC Networks Inc.

AMC Global Media owns several linear TV networks, including AMC, WE tv, BBC America, IFC, and SundanceTV. AMC, its most widely distributed network,reached 55 million pay TV households in the US at the end of 2025. The firm also had nearly 10.5 million US streaming subscribers, with AMC+ as the flagship streaming platform. With both its linear networks and streaming offerings, the firm caters to specific niche audiences. Over the last 15 years, AMC has shifted its focus to original scripted programming from classic movies. It creates content through AMC Studios and also generates revenue from licensing content. Following an international divestiture at the end of 2023, domestic operations make up nearly 90% of total revenue.

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Share on Social Networks: